Samsung Biologics is experiencing a downturn in its stock prices as labor disputes over wages and personnel policies continue to escalate.
As of 3:10 PM on October 27, Samsung Biologics shares were trading at 1,367,000 won, down 85,000 won (5.85%) from the previous trading day, according to the Korea Exchange.
The sharp decline in Samsung Biologics' stock appears to reflect concerns over the prolonged labor conflict. The union is currently at an impasse with management regarding wage and personnel systems. Although a second general strike planned for October 26 was postponed, tensions remain high as the union voted to approve a fund to support alternative forms of protest.
This fund is intended to compensate union members for wage losses incurred during potential strikes. With a full strike becoming increasingly difficult, the union is preparing for other forms of industrial action.
Earlier, on October 16, a court ruling expanded the scope of prohibited labor actions from three processes to nine at Samsung Biologics. However, the ruling limited the scope to work involving already thawed cell lines.
In response, the Samsung Biologics union held a press conference on October 26 at the National Assembly, asserting that the entire production process should not be included in security work under the pretext of continuous processes. They called on the National Assembly and the government to define the scope and criteria for security work.
As of 3:10 PM on October 27, Samsung Biologics shares were trading at 1,367,000 won, down 85,000 won (5.85%) from the previous trading day, according to the Korea Exchange.
The sharp decline in Samsung Biologics' stock appears to reflect concerns over the prolonged labor conflict. The union is currently at an impasse with management regarding wage and personnel systems. Although a second general strike planned for October 26 was postponed, tensions remain high as the union voted to approve a fund to support alternative forms of protest.
This fund is intended to compensate union members for wage losses incurred during potential strikes. With a full strike becoming increasingly difficult, the union is preparing for other forms of industrial action.
Earlier, on October 16, a court ruling expanded the scope of prohibited labor actions from three processes to nine at Samsung Biologics. However, the ruling limited the scope to work involving already thawed cell lines.
In response, the Samsung Biologics union held a press conference on October 26 at the National Assembly, asserting that the entire production process should not be included in security work under the pretext of continuous processes. They called on the National Assembly and the government to define the scope and criteria for security work.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.